Nothing Special   »   [go: up one dir, main page]

EP0866706A1 - Treatment of traumatic brain injury - Google Patents

Treatment of traumatic brain injury

Info

Publication number
EP0866706A1
EP0866706A1 EP96937193A EP96937193A EP0866706A1 EP 0866706 A1 EP0866706 A1 EP 0866706A1 EP 96937193 A EP96937193 A EP 96937193A EP 96937193 A EP96937193 A EP 96937193A EP 0866706 A1 EP0866706 A1 EP 0866706A1
Authority
EP
European Patent Office
Prior art keywords
treatment
tetrahydro
ethyl
tetrazol
traumatic brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP96937193A
Other languages
German (de)
French (fr)
Inventor
Brian R. University of Texas Health Center PIKE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of EP0866706A1 publication Critical patent/EP0866706A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to the use of 5-(2-ethyl-2H-tetrazol-5-yl)-1 ,2,3,6-tetra- hydro-1 -methylpyridine for manufacturing a pharmaceutical preparation for the treatment of traumatic brain injury (TBI).
  • TBI traumatic brain injury
  • EP-A1 0 296 721 disclosed a class of piperidine or 1 ,2,3,6-terahydropyridine com ⁇ pounds substituted in the 5-position with a five-membered heterocyclic group includ ⁇ ing a subclass of optionally substituted 5-tetrazolyl-1 ,2,3,6-tetrahydro-pyridine com ⁇ pounds.
  • the compounds were disclosed to have high affinity to central cholinergic receptors, in particular high affinity for central muscarinic Mi receptors, thus being useful in the treatment of Alzheimer's disease, senile dementia, and impaired learning and memory functions.
  • TBI caused by physical or neurological conditions or various diseases is of in- creasing importance among the population and there is a great demand for effective and safe drugs for the treatment of such disorders and the sequelae thereof.
  • the present invention relates to the use of 5-(2-ethyl-2H-tetrazol-5-yl)- 1 ,2,3,6-tetrahydro-1 -methylpyridine or an acid addition salt thereof
  • traumatic brain injury is in this specification meant to include all conditions associated with trauma to the brain or spinal cord e.g. caused by physical forces acting on the scull or spinal column, ischaemia, stroke, arrested breathing, cardiac arrest, cerebral thrombosis or embolism, neurological problems caused by AIDS, cerebral hemorrhage, encephalomyelitis, hydrocephalus, post-operative events, cerebral infections, concussions or elevated intracranial pressure.
  • the pharmaceutically acceptable acid addition salts of the compounds used in the invention are salts formed with non-toxic organic or inorganic acids.
  • organic salts are those with maleic, fumaric, benzoic, ascorbic, pamoic, suc ⁇ cinic, oxalic, bis-methylenesalicylic, methanesulfonic, ethanedisulfonic, acetic, propi- onic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-amino-benzoic, glutamic, benzene sul ⁇ fonic and theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromo-theophylline.
  • Exemplary of such inorganic salts are those with hydrochlo ⁇ ric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids.
  • the compound used according to the invention has now been found to be useful in the treatment of TBI. So, for example it improves cognitive performance following to moderate traumatic brain injury and it attenuates injury-reduced reductions of cholinergic neurones. Furthermore it has been found not to cause adverse cardiac 5 or other side effects in doses believed to be clinically relevant.
  • the present invention provides a method for the prevention or treatment of TBI in man comprising the step of administering a therapeutically effective amount of 5-(2-ethyl-2H-tetrazol-5-yl)-1 ,2,3,6-tetrahydro-1 -methylpyridine io or acid addition salt thereof to a patient in need thereof.
  • the compound used according to the invention and the pharmaceutically accep ⁇ table acid addition salts thereof may be administered in any suitable way, e.g. orally or parenterally, and the compounds may be presented in any suitable form for such 15 administration, eg. in the form of tablets, capsules, powders, syrups or solutions or dispersions for injection.
  • An effective daily dose of the compound according to the invention or a pharmaceuti ⁇ cally acceptable salt thereof is from 10 ⁇ g/kg to 10 mg/kg body weight, preferably 20 25 ⁇ g/day/kg body weight to 1.0 mg/day/kg body weight. Accordingly, a suitable daily dose is 500 ⁇ g to 600 mg/day, preferably 1.0 mg to 100 mg.
  • the compound used according to the invention may be obtained as described in EP-A1 0 296 721 and the acid addition salts thereof are easily prepared by methods 25 well known in the art.
  • Rats were subjected to central fluid percussion traumatic brain injury as described by Dixon, C.E., et al., J. Neurosurgery, 67 (1987) 110- 119.
  • the injured animals were treated s.c. daily on days 1 -15 postinjury beginning 24 hours after injury with either saline or 5-(2-ethyl-2H-tetrazol-5-yl)-1 , 2, 3, 6-tetrahydro-1 -methylpyridine, 3.6 ⁇ mol/kg or 15 ⁇ mol/kg.
  • Body weight was recorded prior to injury and on Days 1 -5 postinjury and rotarod performance was determined on Days 1-5 post injury according to the method of Hamm, R.J., et al., J. Neurotrauma, 11 (1994) 187-196.
  • the rotarod test was used to measure motor performance following TBI.
  • Shaminjured animals (animals prepared for injury but not delivered a fluid pulse) were included for comparison.
  • cortisol Following perfusion, brains were trimmed into two blocks and postfixed for 24 hours in the same solution at 10 °C. Coronal 40 ⁇ m sections were collected on a vibra- tome through the forebrain nuclei and every fifth section was processed for ChAT immunoreactivity. Parallel sections were stained for Nissi substance with cresyl violet for quantitative assesment of any possible cholinergic and non-cholinergic neuronal loss in the basal forebrain nuclei.
  • Free floating forebrain sections were incubated in a final ChAT antibody concentra ⁇ tion (1 :50) of 1.0 ⁇ g/ml in a 0.01 M phosphate buffered saline (PBS) solution contain ⁇ ing 0.1% triton X-100.
  • the forebrain sections were trimmed and incubated in the pri- mary antibody for 24 hours at room temperature in culture trays (4 sections/300 ⁇ LJwell).
  • the ChAT immunoreactive neurones in the medial septal nucleus (MSN), the vertical limb nucleus of the diagonal band (VDB) and the nucleus basalis magnocel- lularis (NMB) were counted using a Microcomputer Imaging Device system (MCID) (Imaging Research Inc., Ontario, Canada).
  • MSN medial septal nucleus
  • VDB vertical limb nucleus of the diagonal band
  • NMB nucleus basalis magnocel- lularis
  • the boundary between MSN and VDB was defined as the anterior commisure.
  • the NMB was defined as the imunolabelled neurons Iocated in the globulus pallidus and the adjoining part of the intemal capsule.
  • Celle counts were made from each animal obtained at 0.2 mm intervals through the forebrain nuclei. Cell numbers are reported as group means per 10,000 ⁇ m2 for each forebrain nucleus.
  • the pharmaceutical formulations of the invention may be prepared by conventional methods in the art.
  • Tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conven- tional tabletting machine.
  • adjuvants or diluents comprise: corn starch, lactose, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvant or additive colourings, aroma, preservatives etc. may be used provided that they are compatible with the active ingredients.
  • Solutions for injections may be prepared by solving the active ingredient and possible additives in a part of the vehicle, preferably sterile water, adjusting the solution to the desired volume, sterilization of the solution and filling in suitable ampules or vials. Any suitable additive conventionally used in the art may be added, such as tonicity agents, preservatives, antioxidants, etc.
  • Typical examples of recipes for the formulations of the invention are as follows (amounts of active ingredient calculated as the free base):

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The compound 5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetrahydro-1-methylpyridine of formula (I) improves cognitive performance and attenuates injury-reduced reductions of cholinergic neurones in traumatic brain injury models and is useful for the manufacture of a pharmaceutical preparation for the treatment of traumatic brain injury.

Description

Treatment of Traumatic Brain Injury
Field of invention
The present invention relates to the use of 5-(2-ethyl-2H-tetrazol-5-yl)-1 ,2,3,6-tetra- hydro-1 -methylpyridine for manufacturing a pharmaceutical preparation for the treatment of traumatic brain injury (TBI).
Background of the Invention
EP-A1 0 296 721 disclosed a class of piperidine or 1 ,2,3,6-terahydropyridine com¬ pounds substituted in the 5-position with a five-membered heterocyclic group includ¬ ing a subclass of optionally substituted 5-tetrazolyl-1 ,2,3,6-tetrahydro-pyridine com¬ pounds. The compounds were disclosed to have high affinity to central cholinergic receptors, in particular high affinity for central muscarinic Mi receptors, thus being useful in the treatment of Alzheimer's disease, senile dementia, and impaired learning and memory functions.
The structure-activity relationship of this subclass was described by Moltzen et al., J. Med. Chem. 1994, 37, 4085-4099. One of the compounds, i.e. 5-(2-ethyl-2H-tetra- zol-5-yl)-1 , 2,3, 6-tetrahydro-1 -methylpyridine has been reported to be selective for muscarinic receptors with a several fold higher affinity for Mi than for M2 and M3 receptors (Subtypes of Muscarinic Receptors, The Sixth International Symposium, Nov. 9-12, 1994, Fort Lauderdale). Functionally, it has been described to behave as a partial agonist at Mi receptors and an antagonist at M2 and M3 receptors. Furthermore, the only prominent in vivo effect reported was effect on spatial memory acquisition in young and aged rats, respectively.
TBI caused by physical or neurological conditions or various diseases is of in- creasing importance among the population and there is a great demand for effective and safe drugs for the treatment of such disorders and the sequelae thereof.
It has now surprisingly been found that the compound 5-(2-ethyl-2H-tetrazol-5-yl)- 1 ,2, 3, 6-tetrahydro-1 -methylpyridine shows beneficial effects in the treatment of TBI and the sequelae thereof.
Summary of the Invention
Accordingly, the present invention relates to the use of 5-(2-ethyl-2H-tetrazol-5-yl)- 1 ,2,3,6-tetrahydro-1 -methylpyridine or an acid addition salt thereof
for the manufacture of a pharmaceutical preparation for the treatment of traumatic brain injury or sequelae thereof.
The term traumatic brain injury (TBI) is in this specification meant to include all conditions associated with trauma to the brain or spinal cord e.g. caused by physical forces acting on the scull or spinal column, ischaemia, stroke, arrested breathing, cardiac arrest, cerebral thrombosis or embolism, neurological problems caused by AIDS, cerebral hemorrhage, encephalomyelitis, hydrocephalus, post-operative events, cerebral infections, concussions or elevated intracranial pressure.
The pharmaceutically acceptable acid addition salts of the compounds used in the invention are salts formed with non-toxic organic or inorganic acids. Exemplary of such organic salts are those with maleic, fumaric, benzoic, ascorbic, pamoic, suc¬ cinic, oxalic, bis-methylenesalicylic, methanesulfonic, ethanedisulfonic, acetic, propi- onic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-amino-benzoic, glutamic, benzene sul¬ fonic and theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromo-theophylline. Exemplary of such inorganic salts are those with hydrochlo¬ ric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids. The compound used according to the invention has now been found to be useful in the treatment of TBI. So, for example it improves cognitive performance following to moderate traumatic brain injury and it attenuates injury-reduced reductions of cholinergic neurones. Furthermore it has been found not to cause adverse cardiac 5 or other side effects in doses believed to be clinically relevant.
In another aspect, the present invention provides a method for the prevention or treatment of TBI in man comprising the step of administering a therapeutically effective amount of 5-(2-ethyl-2H-tetrazol-5-yl)-1 ,2,3,6-tetrahydro-1 -methylpyridine io or acid addition salt thereof to a patient in need thereof.
The compound used according to the invention and the pharmaceutically accep¬ table acid addition salts thereof may be administered in any suitable way, e.g. orally or parenterally, and the compounds may be presented in any suitable form for such 15 administration, eg. in the form of tablets, capsules, powders, syrups or solutions or dispersions for injection.
An effective daily dose of the compound according to the invention or a pharmaceuti¬ cally acceptable salt thereof is from 10 μg/kg to 10 mg/kg body weight, preferably 20 25 μg/day/kg body weight to 1.0 mg/day/kg body weight. Accordingly, a suitable daily dose is 500 μg to 600 mg/day, preferably 1.0 mg to 100 mg.
The compound used according to the invention may be obtained as described in EP-A1 0 296 721 and the acid addition salts thereof are easily prepared by methods 25 well known in the art.
Pharmacology
The compound used according to the invention was tested by the following well recognized and reliable method:
30
Cognitive Function following to TBI
Rats were subjected to central fluid percussion traumatic brain injury as described by Dixon, C.E., et al., J. Neurosurgery, 67 (1987) 110- 119. The injured animals were treated s.c. daily on days 1 -15 postinjury beginning 24 hours after injury with either saline or 5-(2-ethyl-2H-tetrazol-5-yl)-1 , 2, 3, 6-tetrahydro-1 -methylpyridine, 3.6 μmol/kg or 15 μmol/kg.
Righting reflex suppression after TBI was determined according to the method of Dixon et al. 1987, supra.
Body weight was recorded prior to injury and on Days 1 -5 postinjury and rotarod performance was determined on Days 1-5 post injury according to the method of Hamm, R.J., et al., J. Neurotrauma, 11 (1994) 187-196. The rotarod test was used to measure motor performance following TBI.
Finally, mean latency (+S.E.M.) to find the goal platform in the Morris water maze was measured on days 11-15 postinjury. The results were analysed by an ANOVA. During the water maze testing all animals were injected 10 minutes prior to assess- ment in the water maze.
Shaminjured animals (animals prepared for injury but not delivered a fluid pulse) were included for comparison.
Qantif ication of ChAT neurones following to TBI
Rats were subjected to central fluid percussion TBI and treated as described above. They were injected s.c. with saline (n=5) or test compound (5-(2-ethyl-2H-tetrazol-5- yl)-1 , 2, 3, 6-tetrahydro-1 -methylpyridine, 15 μmol/kg) (n=5) . Shaminjured rats were injected (s.c.) with saline (n=4) or test compound 15 μmol/kg (n=4).
Righting reflex suppression was determined as described above.
Possible loss of cholinergic neurones following to TBI was determined by quantifica¬ tion of choline acethyltransferase (ChAT) immunoreactivity neurones in basal fore- brain. On day 15 post-injury (2-4 hours following last injection) all animals were ane¬ sthetized with pentobarbital (90 mg/kg, i.p.) and perfused transaortically with 200- 250 ml of isotonic saline followed by 500 ml of 4.0% paraformaldehyde/0.2% picric acid in 0.1 M phosphate buffer at a rate of 500 ml/30 min at room temperature. Following perfusion, brains were trimmed into two blocks and postfixed for 24 hours in the same solution at 10 °C. Coronal 40 μm sections were collected on a vibra- tome through the forebrain nuclei and every fifth section was processed for ChAT immunoreactivity. Parallel sections were stained for Nissi substance with cresyl violet for quantitative assesment of any possible cholinergic and non-cholinergic neuronal loss in the basal forebrain nuclei.
Free floating forebrain sections were incubated in a final ChAT antibody concentra¬ tion (1 :50) of 1.0 μg/ml in a 0.01 M phosphate buffered saline (PBS) solution contain¬ ing 0.1% triton X-100. The forebrain sections were trimmed and incubated in the pri- mary antibody for 24 hours at room temperature in culture trays (4 sections/300 μLJwell).
After 4 washes in PBS, the sections were incubated in the secondary antibody (horse antimouse IgG; Vector Laboratories, Burlingame, CA) for 1 hour at 37°C. After 3 washes in PBS, the sections were incubated with mouse avidin-biotin-peroxi- dase complex (ABC) (Vector) technique (Hsu et al J. Histochem. Cytochem. 29, 1981, 577-580) for 2 hours at 37°C. Following three washes with PBS and one in 0.1 M Tris-buffered saline (TBS), free floating sections were processed by the gucose oxidase-diaminobezidine-nickel method described by Shu et al. Neurosci. Lett. 85 1988, 169-171. The reaction was stopped by transferring the sections into TBS. The sections were mounted on gelatin-chrome alum coated glass slides and allowed to dry overnight at room temperature, dehydrated in ascending concentra¬ tions of ethanol and xylene, and then coverslipped with Permount.
The ChAT immunoreactive neurones in the medial septal nucleus (MSN), the vertical limb nucleus of the diagonal band (VDB) and the nucleus basalis magnocel- lularis (NMB) were counted using a Microcomputer Imaging Device system (MCID) (Imaging Research Inc., Ontario, Canada). The boundary between MSN and VDB was defined as the anterior commisure. The NMB was defined as the imunolabelled neurons Iocated in the globulus pallidus and the adjoining part of the intemal capsule. Celle counts were made from each animal obtained at 0.2 mm intervals through the forebrain nuclei. Cell numbers are reported as group means per 10,000 μm2 for each forebrain nucleus. Neurons of the MSN, VDB and NMB from parallel sections stained for cresyl violet were also counted on the MCID. Because of the large number of the total choliner- gic and non-cholinergic neurons that stain for cresyl violet throughout these regions, a bilatetral sample of beurons was couted in each nucleus. A grid with predeter- mined areas was used to count cells for each nucleus, For MSN and VDB nuclei, three 2,000 μm≥ regions were counted on each side (thus a total area of 12,000 μm2 was sampled for each nucleus in each of the four section counted). For the NMB, one 12,000 μm2 region was counted on each side (total area=24,000 μm2 in each of the four section counted). Only large cells (>20 μm diameter) with visible somatic Nissi bodies and with a clear neuronal type nucleus were quantified.
Results
There were no significant differences between any of the injured animals on righting reflex suppression after TBI. This indicates that within each experiment the injury groups received an equivalent severity of injury. Sham-injured animals righted significantly faster than any of the TBI animals (p < 0.0001 for each comparison). Suppression of righting in the sham-injured group is due to the gas anesthesia used prior to injury.
There was no significant difference between any of the injured groups on loss of body weight following TBI, again indicating an equivalent injury severity between injured groups.
There were no significant differences on rotarod performance on Days 1-5 post injury between any of the injured groups. Because test compound was administered on Days 1 -15 postinjury, these tests also indicate that the drug had no effect on body weight or rotarod performance following injury.
ANOVA indicated that the injured animals injected (s.c.) daily with test compound performed better in Morris water maze than injured saline treated animals. Injured animals treated with test compound 15 μmol/kg significantly improved performance with p < 0.01. TBI caused a significant reduction in the number of ChAT-IR neurons in VDB and NMB in rats treated with saline and test compound, respectively. However, the compound of the invention significally attenuated injury reduced reductions in ChAT- IR (32% reduction as compared to injured saline treated group in VDB and 51% in , NMB). The parallel cresyl violet stained sections showed no decrease in cell numbers in the MSN, VDB or NMB indicating that the loss in ChAT-IR neurons does not result from cell death.
Formulation Examples
The pharmaceutical formulations of the invention may be prepared by conventional methods in the art.
For example: Tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conven- tional tabletting machine. Examples of adjuvants or diluents comprise: corn starch, lactose, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvant or additive colourings, aroma, preservatives etc. may be used provided that they are compatible with the active ingredients.
Solutions for injections may be prepared by solving the active ingredient and possible additives in a part of the vehicle, preferably sterile water, adjusting the solution to the desired volume, sterilization of the solution and filling in suitable ampules or vials. Any suitable additive conventionally used in the art may be added, such as tonicity agents, preservatives, antioxidants, etc.
Typical examples of recipes for the formulations of the invention are as follows (amounts of active ingredient calculated as the free base):
1 ) Tablets:
5-(2-ethyl-.?H-tetrazol-5-yl)-1 ,2,3,6-tetrahydro-1 -methyl- pyridine 20 mg
Lactose 60 mg
Maize starch 30 mg
Hydroxypropylcellulose 2.4 mg
Microcrystalline cellulose 19.2 mg Croscarmellose Sodium Type A 2.4 mg
Magnesium stearate 0.84 mg
2) Tablets: 5-(2-ethyl-2H-tetrazol-5-yl)-1 ,2,3,6-tetrahydro-1 -methyl¬ pyridine 10 mg Lactose 46.9 mg Maize starch 23.5 mg Povidone 1.8 mg Microcrystalline cellulose 14.4 mg
Croscarmellose Sodium Type A 1.8 mg
Magnesium stearate 0.63 mg
3) Syrup:
5-(2-ethyl-2/-/-tetrazol-5-yl)- •1 ,2,3,6 -tetrahydro-' 1 -methyl pyridine 5.0 mg
Sorbitol 500 mg
Hydroxypropylcellulose 15 mg
Glycerol 50 mg
Methyl-paraben 1 mg
Propyl-paraben 0.1 mg
Ethanol 0.005 ml
Flavour 0.05 mg
Saccharin natrium 0.5 mg
Water ad 1 ml
4) Solution:
5-(2-ethyl-2r-/-tetrazol-5-yl)-1 ,2,3,6-tetrahydro-1 -methyl¬ pyridine 1 -0 mg Sorbitol 5.1 mg Acetic acid 0.08 mg Water for injection ad 1 ml

Claims

1. Use of 5-(2-ethyl-2H-tetrazol-5-yl)-1 ,2,3,6-tetrahydro-1 -methylpyridine
or a pharmaceutically acceptable acid addition salt thereof for the manufacture of a pharmaceutical preparation for the treatment of traumatic brain injury.
2. Use according to any of claim 1 , characterised in that the pharmaceutical pre¬ paration manufactured comprises 5-(2-ethyl-_?H-tetrazol-5-yl)-1 ,2,3,6-tetrahydro-1- methylpyridine or a pharmaceutically acceptable acid addition salt thereof in a unit dosis form.
3. Use according to Claim 1 , characterised in that the pharmaceutical prepara¬ tion manufactured comprises 5-(2-ethyl-2H-tetrazol-5-yl)-1 ,2,3,6-tetrahydro-1 -methyl¬ pyridine or a pharmaceutically acceptable acid addition salt thereof in an amount of 500 μg to 600 mg/day, preferably 1.0 mg to 100 mg/day.
4. Use according to any of claims 1-3, characterised in that the pharmaceutical preparation manufactured is for the treatment of traumatic brain injury caused by physical forces acting on the scull or spinal column, ischaemia, stroke, arrested breathing, cardiac arrest, cerebral thrombosis or emboism, neurological problem caused by AIDS, cerebral hemorrhage, encephalomyelitis, hydrocephalus, post-ope¬ rative events, cerebral infections, concussions or elevated intracranial pressure and or for the treatment of the sequelae of such a condition.
EP96937193A 1995-11-06 1996-11-05 Treatment of traumatic brain injury Ceased EP0866706A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK123295 1995-11-06
DK123295 1995-11-06
PCT/DK1996/000458 WO1997017074A1 (en) 1995-11-06 1996-11-05 Treatment of traumatic brain injury

Publications (1)

Publication Number Publication Date
EP0866706A1 true EP0866706A1 (en) 1998-09-30

Family

ID=8102484

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96937193A Ceased EP0866706A1 (en) 1995-11-06 1996-11-05 Treatment of traumatic brain injury

Country Status (18)

Country Link
EP (1) EP0866706A1 (en)
JP (1) JPH11514654A (en)
KR (1) KR19990067353A (en)
AU (1) AU706594B2 (en)
BG (1) BG63150B1 (en)
BR (1) BR9611396A (en)
CA (1) CA2234824A1 (en)
CZ (1) CZ287441B6 (en)
EA (1) EA000531B1 (en)
HU (1) HUP9901051A2 (en)
IS (1) IS4726A (en)
NO (1) NO982036L (en)
NZ (1) NZ321546A (en)
PL (1) PL326490A1 (en)
SK (1) SK58198A3 (en)
TR (1) TR199800801T2 (en)
WO (1) WO1997017074A1 (en)
ZA (1) ZA969320B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013096A1 (en) * 1997-07-01 2000-12-13 Lundbeck & Co As H SALE OF ADDITION OF MALEIC ACID OF 5- (2-ETIL-2-H-TETRAZOL-5-IL) -1-METHYL-1,2,3,6-TETRAHIDROPIRIDINA, PHARMACEUTICAL COMPOSITION THAT CONTAINS IT, ITS USE IN THERAPY AND METHOD OF PREPARATION OF THE SAME.
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (en) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド Neurogenesis by angiotensin regulation
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
US5328925A (en) * 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5330994A (en) * 1992-03-24 1994-07-19 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9717074A1 *

Also Published As

Publication number Publication date
AU706594B2 (en) 1999-06-17
NO982036D0 (en) 1998-05-05
JPH11514654A (en) 1999-12-14
BG102480A (en) 1999-01-29
HUP9901051A2 (en) 2000-03-28
ZA969320B (en) 1997-05-30
CZ287441B6 (en) 2000-11-15
MX9803432A (en) 1998-09-30
CA2234824A1 (en) 1997-05-15
NZ321546A (en) 2000-12-22
BG63150B1 (en) 2001-05-31
NO982036L (en) 1998-06-25
PL326490A1 (en) 1998-09-28
KR19990067353A (en) 1999-08-16
BR9611396A (en) 1999-07-13
EA199800434A1 (en) 1998-10-29
CZ138998A3 (en) 1998-10-14
IS4726A (en) 1998-04-27
SK58198A3 (en) 1998-10-07
WO1997017074A1 (en) 1997-05-15
EA000531B1 (en) 1999-10-28
TR199800801T2 (en) 1998-08-21
AU7490096A (en) 1997-05-29

Similar Documents

Publication Publication Date Title
DE3650733T2 (en) Pharmaceutical preparations and medical uses of dioxopiperidine derivatives, in particular as an enhancer of the immune response and as antiviral and antibacterial agents
RU2469723C2 (en) Therapeutic agent containing carbostiryl derivative and donepezil for treating alzheimer&#39;s disease
EP0615751B1 (en) Use of tachykinin antagonists in the treatment of emesis
HU202108B (en) Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
WO1994002150A1 (en) Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity
CZ154897A3 (en) Liquid preparation for oral administration
DE69525354T2 (en) A NEW MEDICAL USE OF A 5HT 3 ANTAGONIST
US5290783A (en) Use of spiperone derivatives as immunosuppressant agents
US6297262B1 (en) Treatment of schizophrenia and psychosis
TW198717B (en)
AU706594B2 (en) Treatment of traumatic brain injury
EP0275668B1 (en) Use of ketone derivatives in the treatment of cognitive disorders
AU764304B2 (en) Use of saredutant and of its pharmaceutically acceptable salts for the preparation of medicinal products that are useful in the treatment or prevention of major depressive disorders
US6610720B2 (en) Method for treating or preventing emesis
TW304879B (en)
CA2159091C (en) Topical and systemic application of buspirone or derivatives thereof for treatment of pathological conditions associated with immune responses
MXPA98003432A (en) Treatment of traumat cerebral damage
CZ2001150A3 (en) Medicament for treating psychoses or other neuropsychiatric symptoms in patients suffering from Alzheimer&#39;s disease
US20030166667A1 (en) Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
JPH1160482A (en) Sexual function-improving agent
MXPA01000466A (en) Method of treatment
JPH01250319A (en) Drug

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980608

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 980608;LT PAYMENT 980608;LV PAYMENT 980608;RO PAYMENT 980608;SI PAYMENT 980608

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

17Q First examination report despatched

Effective date: 20010308

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20010903